27 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26288158	13	Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes.	University of Michigan
25358116	84	Synthesis of 7-halogenated isatin sulfonamides: nonradioactive counterparts of caspase-3/-7 inhibitor-based potential radiopharmaceuticals for molecular imaging of apoptosis.	Westf£Lische Wilhelms-Universit£T M£Nster
23411396	60	Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: nonradioactive counterparts of putative PET-compatible apoptosis imaging agents.	Westf£Lische Wilhelms-Universit£T M£Nster
24900651	50	Irreversible inhibitors of cysteine proteases.	Dart Neuroscience
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
14980679	30	Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid.	Maxim Pharmaceuticals
21441025	147	Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.	Washington University
19908842	84	Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.	National Human Genome Research Institute
19445513	82	Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis.	Westfalische Wilhelms-Universitat
19049429	70	Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.	Imperial College
17889532	23	Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P(2) amino acid by 2-aminoaryl acids and other non-natural amino acids.	Epicept
17585855	65	Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors.	Washington University
17181147	10	Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.	University of Edinburgh
17154501	121	5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis.	University Hospital of The WestfäLische Wilhelms-UniversitäT
16891117	5	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis.	Washington University
15713391	19	Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 alpha-amino acid by a alpha-hydroxy acid.	Maxim Pharmaceuticals
15686936	210	Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.	Merck Frosst Centre For Therapeutic Research
15109679	15	Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.	Idun Pharmaceuticals
12270186	99	Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.	Idun Pharmaceuticals
12270185	257	Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.	Idun Pharmaceuticals
29648825	47	Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.	Nestl�
9108306	17	Molecular cloning and characterization of a new receptor for galanin.	Merck Research Laboratories
18800762	61	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.	National Taiwan University
18308563	39	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.	Irbm/Merck Research Laboratories
17685602	33	Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.	Targegen
14698155	68	Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.	Bristol-Myers Squibb